EA200801666A1 - КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И ИНГИБИТОРОВ HMG-CoA РЕДУКТАЗЫ - Google Patents

КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И ИНГИБИТОРОВ HMG-CoA РЕДУКТАЗЫ

Info

Publication number
EA200801666A1
EA200801666A1 EA200801666A EA200801666A EA200801666A1 EA 200801666 A1 EA200801666 A1 EA 200801666A1 EA 200801666 A EA200801666 A EA 200801666A EA 200801666 A EA200801666 A EA 200801666A EA 200801666 A1 EA200801666 A1 EA 200801666A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hmg
combination
triazine derivatives
coa reductase
reductase inhibitors
Prior art date
Application number
EA200801666A
Other languages
English (en)
Russian (ru)
Inventor
Жерар Муэне
Даньель Краво
Дидье Месанжо
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA200801666A1 publication Critical patent/EA200801666A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
EA200801666A 2006-01-13 2006-12-18 КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И ИНГИБИТОРОВ HMG-CoA РЕДУКТАЗЫ EA200801666A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600343A FR2896158B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
PCT/EP2006/012184 WO2007079916A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes

Publications (1)

Publication Number Publication Date
EA200801666A1 true EA200801666A1 (ru) 2008-12-30

Family

ID=36649749

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801666A EA200801666A1 (ru) 2006-01-13 2006-12-18 КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И ИНГИБИТОРОВ HMG-CoA РЕДУКТАЗЫ

Country Status (14)

Country Link
US (1) US20100158999A1 (enExample)
EP (1) EP1978951A2 (enExample)
JP (1) JP2009523141A (enExample)
KR (1) KR20080085208A (enExample)
CN (1) CN101355935A (enExample)
AR (1) AR059031A1 (enExample)
AU (1) AU2006334733A1 (enExample)
BR (1) BRPI0621420A2 (enExample)
CA (1) CA2636840A1 (enExample)
EA (1) EA200801666A1 (enExample)
FR (1) FR2896158B1 (enExample)
IL (1) IL192594A0 (enExample)
WO (1) WO2007079916A2 (enExample)
ZA (1) ZA200806937B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP5320399B2 (ja) * 2007-08-31 2013-10-23 ハナル バイオファーマ カンパニーリミテッド １，３，５−トリアジン−２，４，６−トリアミン化合物またはその薬学的に許容可能な塩と、それを含む薬学組成物
CA2745854A1 (en) * 2008-12-12 2010-06-17 Daniel Cravo Tetrahydrotriazine compounds for treating diseases associated with ampk activity
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) * 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
WO2021117861A1 (ja) * 2019-12-13 2021-06-17 大日本住友製薬株式会社 製造性及び溶出性に優れた小型錠剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin

Also Published As

Publication number Publication date
FR2896158B1 (fr) 2008-09-12
ZA200806937B (en) 2009-07-29
EP1978951A2 (en) 2008-10-15
US20100158999A1 (en) 2010-06-24
AU2006334733A1 (en) 2007-07-19
AR059031A1 (es) 2008-03-12
KR20080085208A (ko) 2008-09-23
WO2007079916A2 (en) 2007-07-19
CN101355935A (zh) 2009-01-28
JP2009523141A (ja) 2009-06-18
IL192594A0 (en) 2009-09-22
BRPI0621420A2 (pt) 2011-12-06
FR2896158A1 (fr) 2007-07-20
WO2007079916A3 (en) 2007-12-06
CA2636840A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
ATE496029T1 (de) Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
ECSP066893A (es) Inhibidores de proteínas de apoptosis (iap)
NO20081636L (no) FAP - inhibitorer
DK1761520T3 (da) Kinaseinhibitorer
ATE499097T1 (de) Monozyklische heterozyklen als kinase-hemmer
TW200640924A (en) VEGF-R2 inhibitors and methods
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
EA200802285A1 (ru) Бивалентные миметики smac и их применения
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EP2036552A4 (en) SENESCENCE INHIBITOR
WO2006052568A3 (en) Tgf-beta inhibitors
CY1115462T1 (el) ΣΥΝΔΥΑΣΜΟΣ ΑΝΑΣΤΟΛΕΩΝ ΗΜG-CoΑ ΑΝΑΓΩΓΑΣΗΣ ΑΤΟΡΒΑΣΤΑΤΙΝΗΣ Ή ΣYΜΒΑΣΤΑΤΙΝΗΣ ΜΕ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ 4 ΟΠΩΣ ΡΟΦΛΟΥΜΙΛΑΣΤΗ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΦΛΕΓΜΟΝΩΔΩΝ ΠΝΕΥΜΟΝΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
DK2315590T3 (da) Pyrrolinhibitorer af S-nitrosoglutathionreduktase
IL192594A0 (en) Combination of triazine derivatives and hmg-coa reductase inhibitors
DOP2005000010A (es) Inhibidores de quinasa
CY1111768T1 (el) Νεος παραγοντας μειωσης τριγλυκεριδιου
EA200801676A1 (ru) Комбинация производных триазина и сенсибилизаторов инсулина
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
DE60233899D1 (de) Neue boronatester
EA201101195A1 (ru) Производные розувастатина и аторвастатина
BRPI0509926A (pt) imidazóis